Back to the screening list

Screening rules

Does one dose of psilocybin rewire the brain?

The rules every screening decision was made under, as committed. Dated 8 November 2026.

sha256 18a0c0402f2448f1df69342f8a2c53f0e76c4d8f5cfae00e0c052f80ce0567da

Note on category D, added 9 November 2026. D2 studies report patient outcomes and do not by themselves show brain change. The rule text below is unchanged, because every decision records the version of the rules it was made under.

# Re-screening brief (three tiers): psilocybin synthesis, 4 Nov 2026 scan

PsychDoc's living synthesis asks "Does one dose of psilocybin rewire the brain?" (psychdoc.ai/evidence/psilocybin-rewiring). On 8 Nov 2026 the owner replaced the in-or-out rules with three tiers, so that evidence able to weaken the headline (null results, failed replications, behavioural persistence, mechanism tests) is admitted and labelled instead of hidden. You are re-tiering works already screened once under the old rules. Each input row carries the old decision for reference only. Judge afresh from the title and abstract.

## What "rewire" means here
A change in brain structure, function, network organization, or molecular or cellular plasticity that is measured after the acute drug effect has ended, following one or a few doses. Record dose count and time from last dose to measurement as the paper states them; never infer them.

## Tiers

**D. Direct evidence** (counted as evidence; can show whether and how psilocybin changes the brain)
- D1. Empirical study, human or animal, measuring brain structure, function, network organization, or molecular or cellular plasticity after psilocybin or psilocin, at any timepoint.
- D2. Human patient trial reporting clinical outcomes after one to three psilocybin or psilocin administrations, without a qualifying post-dose brain measurement. Use D1 whenever the paper reports a qualifying post-dose brain measurement, including acute measurements.
- D3. Mechanistic plasticity or critical-period study with a psilocybin or psilocin arm.

**I. Indirect evidence** (counted separately and labelled; can test or qualify the reading but cannot by itself show brain change after psilocybin)
- I1. Animal studies of psilocybin with behavioural outcomes only that test persistence, replication, dose, context or receptor dependence. Null and failed-replication results count.
- I2. Controlled human studies of psilocybin reporting lasting psychological or behavioural outcomes in healthy volunteers.
- I3. Pharmacological blocking or receptor-manipulation studies of psilocybin's effects, even without a brain measure.
- I4. Original studies of serotonergic psychedelics other than psilocybin or psilocin qualify when they measure structural or molecular plasticity, or a specified proxy such as synaptic markers, BDNF, TrkB, plasticity-related gene expression, or receptor adaptation. These assays may be acute. Studies measuring only brain activity or connectivity qualify only when the measurement occurs after acute drug effects have ended. Acute receptor activation, acute connectivity, computational entropy interpreted as plasticity, and delayed readout of an acute activity tag do not qualify by themselves. Name the tested drug and qualifying assay. Identify peripheral biomarkers as peripheral. Always flag "other-drug".
- I5. Studies that test how a brain measure used in this evidence should be interpreted under psychedelics (for example neurovascular coupling and fMRI), whether or not psilocybin is used.
- I6. Studies whose qualifying psilocybin or psilocin results follow more than three administrations and would otherwise qualify as Direct. One to three administrations count as a few. The word "repeated" alone does not establish I6 eligibility. If separate qualifying one-to-three-dose results exist, classify those results under the applicable Direct rule and describe the longer regimen separately.

**C. Context** (listed, not counted as evidence; used to check coverage and interpretation)
- Context contains reviews, meta-analyses, commentaries, editorials, viewpoints, protocols, conference abstracts without data, and books or chapters without original data that discuss psilocybin, other serotonergic psychedelics, or interpretation of brain measurements under psychedelics. Works without this content are excluded under X1 if they concern another drug, or X3 otherwise. Publication type alone does not establish relevance.

**X. Excluded**
- X1. Other drugs (including ketamine, non-hallucinogenic analogues, cannabis, SSRIs alone) with no psilocybin arm and no fit under I4 or I5.
- X2. Psilocybin work with non-neural, non-persistence outcomes only: pharmacokinetics, epidemiology, policy, ethics, law, use surveys, qualitative process themes.
- X3. Methods tools, rating scales, diagnostic manuals or software not specific to psychedelic brain measures, and anything off-topic.

## Conventions
- Pick one tier and rule using these exceptions and priorities. I6 takes priority over Direct when the qualifying psilocybin or psilocin regimen exceeds three administrations. Otherwise use D1 for brain measurements after dosing humans or animals, D3 for qualifying mechanistic plasticity or critical-period experiments not covered by D1, and D2 for qualifying patient trials without a post-dose brain measurement. D3 requires a plasticity or critical-period result in the psilocybin or psilocin arm itself. A measurement-validity study that meets a Direct rule remains Direct and receives the "measurement-validity" flag; otherwise use I5. For animal studies meeting both I1 and I3, use I1 when post-acute behavioural persistence is measured and I3 otherwise. References to psilocybin in I1, I3 and I6 also include psilocin. Apply the Context scope rule only after checking the empirical evidence rules.
- A rating-scale paper that reports trial outcomes between arms is D2 with flag "secondary-analysis", not X3.
- Classify secondary analyses by their reported measurements: D1 for qualifying post-dose brain measurements, D2 for patient clinical outcomes without such measurements, and I2 for controlled healthy-volunteer studies of lasting psychological or behavioural outcomes. Add "secondary-analysis". A rating-scale analysis follows the same rules.
- Baseline-only prediction studies (brain measured before dosing only) in a psilocybin trial are D2 with flag "no-post-dose-brain".
- Undecidable from what you can see: tier "P" (pending) with the reason naming what is missing. Never guess.
- When the abstract is missing or cannot establish eligibility, retrieve it from Europe PMC or Crossref, or consult an accessible full text. Preserve any retrieved abstract as "fetchedAbstract". When a decision relies on full text, use basis "full-text" and record the source URL, section or figure, and the decisive quoted passage in "fullTextEvidence". A controller summary alone is not the source passage.

## Fields
- relevance 0 to 3: 3 central (brain change one week or more after one or a few doses, or a direct test of that, including nulls); 2 relevant; 1 peripheral; 0 off-topic.
- doses records psilocybin or psilocin administrations per participant or animal in the relevant regimen. Use 1, 2 or 3 for a stated fixed count, [1,2] for one or two administrations, and [1,2,3] for one to three administrations. Use "repeated" only when the regimen exceeds three administrations, "none" when neither drug was administered to a participant or animal, and "not-stated" when the count cannot be established. Do not count placebo sessions or combine separate experimental groups. Describe cell-culture exposure in the reason rather than treating it as an organism dose.
- followUp identifies the measured outcome, elapsed time and reference point as stated by the source. Prefer time since the final relevant dose when reported. Otherwise retain the stated reference point, such as first dose, treatment start or study endpoint, and say when the reference point is unspecified. Never silently convert a study week into time since the final dose. Record different brain and behavioural measurement times separately. Use "not-stated" when timing is unavailable and "n/a" when it does not apply.
- flags (any): lasting-brain, post-acute-brain, acute-brain, measurement-validity, null-or-nonreplication, clinical-trial, healthy-volunteers, animal, human, other-drug, secondary-analysis, preprint, no-post-dose-brain, systematic-review, no-abstract. Use acute-brain for brain measurements during acute drug effects. Use post-acute-brain when the source establishes that brain measurements occurred after acute effects ended. Also use lasting-brain when a brain measurement occurred at least seven days after the relevant final dose. These flags describe measurement timing, including null results, and do not establish that a change occurred. Do not transfer behavioural follow-up times to brain measurements or treat an unspecified number of days as seven days.

## Output
Write a JSON array to your output path, one object per input row, same order:
{"openalexId": "...", "doi": "...", "title": "...", "tier": "D" | "I" | "C" | "X" | "P", "rule": "D1".."D3" | "I1".."I6" | "C" | "X1".."X3" | "P", "relevance": 0-3, "doses": ..., "followUp": "...", "reason": "one plain sentence under 30 words naming what the work is and why this tier", "basis": "abstract" | "title-only" | "fetched-abstract" | "full-text", "flags": [...], "changedFromOld": true | false, "by": "claude-opus-5-5", "at": "2026-11-08"}
plus "fetchedAbstract" when you fetched one. Reasons are published later beside the decision: plain words, no em-dashes.

Then reply with: counts by tier and rule, every row where the tier changed from the old decision's meaning (old include to I/C/X, old exclude to D/I), every P with its reason, and any rule you found unclear. Nothing else.

© 2026 Violema, Inc.